Early treatment correlates with better immune fitness, marked by higher CD4-positive naive T cells and a favorable tumor microenvironment. Cilta-cel therapy shows improved outcomes in earlier ...

The 2-year event-free survival (EFS) rate in the treatment arm was 76.3% (95% CI, 61.1%-86.1%), and the 2-year overall survival (OS) rate was 82.0% (95% CI, 67.1%-90.6%). These results showed that the ...

Outcomes at one year demonstrated that high-degree mismatching did not adversely affect patient survival when PTCy was ...

Critically, metastatic recurrence has significant prognostic implications. In this cohort, patients who experienced ...

Discover the most anticipated breast cancer research at SABCS 2025, featuring groundbreaking abstracts in HR+, HER2+, and ...